Orchid Pharma Share Price

Overview
Recos
News
Analysis
Financials
Forecast
Technicals
Peers
Shareholdings
MF
F&O
Corp Actions
About

Orchid Pharma Share Price

917.1071.15 (8.42%)

Closed
As On: 12 Jun, 2026, 03:52 PM IST
As On: 12 Jun, 2026, 03:55 PM IST

Sector: Pharmaceuticals
Industry: Pharma - Indian

1D
1W
1M
3M
6M
1Y
5Y

Loading...

Try ETMarkets GPTNEW

Open	847.00
High	935.00
Low	847.00
Prev Close	845.95
Volume	4,96,587
VWAP(₹)	909.61

Key Metrics

PE Ratio(x)	228.53
EPS - TTM(₹)	4.01
MCap(₹ Cr.)	4,651.45
MCap Rank	61
PB Ratio(x)	3.35
Div Yield(%)	-
Face Value(₹)	10.00
52W High(₹)	935.00
52W Low(₹)	480.00
MCap/Sales	2.99
Beta(1 Month)	0.76
BV/Share(₹)	253.91

Orchid Pharma share price insights

Quarterly Topline Performance
Company witnessed QoQ revenue growth of 15.07%, which is highest in the last 3 years. (Source: Consolidated Financials)
Topline Contraction
Sales de-grew by 10.84%. Company witnessed revenue contraction for the first time in last 3 years. (Source: Consolidated Financials)
Employee & Interest Expense
Company has spent 1.63% of its operating revenues towards interest expenses and 11.27% towards employee cost in the year ending Mar 31, 2026. (Source: Consolidated Financials)
Orchid Pharma Share Price Update
Orchid Pharma Ltd. share price moved up by 8.42% from its previous close of Rs 845.95. Orchid Pharma Ltd. stock last traded price is 917.10
Share Price Value
Today/Current/Last 917.10917.00
Previous Day 845.95852.45

Found Insights useful?

Orchid Pharma Share Price Returns

1 Day	8.42%
1 Month	29.42%
3 Months	69.57%
1 Year	27.26%
3 Years	120.91%
5 Years	-31.78%

Orchid Pharma Share Recommendations

Mean recosCurrent

STRONG BUY

1 Analysts

Strong
SellSellHoldBuyStrong
Buy

Analyst Trends

Ratings	Current	1W Ago	1M Ago	3M Ago
Strong Buy	1	1	1	2
Buy	-	-	-	-
Hold	-	-	-	-
Sell	-	-	-	-
Strong Sell	-	-	-	-
# Analysts	1	1	1	2

View all Stock Recommendations

News & Analysis

View all Orchid Pharma Share News & Announcements

Share Analysis

EARNINGS

FUNDAMENTAL

RELATIVE VALUATION

RISK

PRICE MOMENTUM

Unlock Stock Score, Analyst' Ratings & Recommendations

Score on 10-point scale
Ratings by analysts
Stock performance

JOIN ET PRIME

Financials

	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025
Total Income	244.95	212.88	204.30	184.38	241.38
Total Income Growth (%)	15.07	4.20	10.81	-23.61	6.88
Total Expenses	219.07	221.85	203.90	167.41	218.37
Total Expenses Growth (%)	-1.25	8.80	21.80	-23.34	9.41
EBIT	25.88	-8.97	0.40	16.97	23.01
EBIT Growth (%)	-	-2,356.84	-97.66	-26.25	-12.34
Profit after Tax (PAT)	23.78	-12.61	-5.72	14.91	22.29
PAT Growth (%)	-	-	-138.39	-33.12	7.31
EBIT Margin (%)	10.56	-4.21	0.19	9.20	9.53
Net Profit Margin (%)	9.71	-5.93	-2.80	8.09	9.24
Basic EPS (₹)	4.69	-2.49	-1.13	2.94	4.40

	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025
Total Income	250.90	217.86	208.95	188.86	243.74
Total Income Growth (%)	15.17	4.26	10.64	-22.51	7.24
Total Expenses	217.22	220.51	202.99	167.40	211.91
Total Expenses Growth (%)	-1.49	8.63	21.25	-21.00	6.18
EBIT	33.68	-2.66	5.96	21.45	31.83
EBIT Growth (%)	-	-144.52	-72.20	-32.59	14.92
Profit after Tax (PAT)	30.60	-5.82	2.23	18.20	27.85
PAT Growth (%)	-	-361.05	-87.74	-34.66	16.49
EBIT Margin (%)	13.42	-1.22	2.85	11.36	13.06
Net Profit Margin (%)	12.20	-2.67	1.07	9.64	11.43
Basic EPS (₹)	6.03	-1.15	0.44	3.59	5.49

	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Revenue	846.50	949.40	850.23	685.33	568.56
Total Revenue Growth (%)	-10.84	11.66	24.06	20.54	22.20
Total Expenses	818.91	853.84	758.29	669.29	625.46
Total Expenses Growth (%)	-4.09	12.60	13.30	7.01	11.58
Profit after Tax (PAT)	20.55	99.66	92.17	46.32	-1.95
PAT Growth (%)	-79.38	8.13	98.99	-	-
Operating Profit Margin (%)	5.03	11.94	13.21	7.24	-4.44
Net Profit Margin (%)	2.53	10.80	11.24	6.95	-0.34
Basic EPS (₹)	4.05	19.65	19.06	11.35	-0.48

	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Revenue	866.57	953.86	849.76	685.33	565.98
Total Revenue Growth (%)	-9.15	12.25	23.99	21.09	23.80
Total Expenses	814.79	847.37	758.23	669.29	618.75
Total Expenses Growth (%)	-3.85	11.76	13.29	8.17	11.88
Profit after Tax (PAT)	45.21	106.48	94.75	54.19	-4.81
PAT Growth (%)	-57.54	12.38	74.85	-	-
Operating Profit Margin (%)	8.01	13.12	13.16	7.24	6.14
Net Profit Margin (%)	5.57	11.55	11.56	8.13	-0.86
Basic EPS (₹)	8.91	20.99	19.59	13.28	-1.18

All figures in Rs Cr, unless mentioned otherwise

Insights

Quarterly Topline Performance
Company witnessed QoQ revenue growth of 15.07%, which is highest in the last 3 years. (Source: Consolidated Financials)
Topline Contraction
Sales de-grew by 10.84%. Company witnessed revenue contraction for the first time in last 3 years. (Source: Consolidated Financials)

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Assets	1,910.91	1,687.91	1,553.87	1,225.21	1,110.56
Total Assets Growth (%)	13.21	8.63	26.83	10.32	-10.24
Total Liabilities	623.13	420.63	384.41	536.56	463.18
Total Liabilities Growth (%)	48.14	9.42	-28.36	15.84	-20.73
Total Equity	1,287.79	1,267.29	1,169.47	688.65	647.38
Total Equity Growth (%)	1.62	8.36	69.82	6.37	-0.85
Current Ratio (x)	2.45	2.83	3.04	1.35	1.87
Total Debt to Equity (x)	0.28	0.14	0.11	0.48	0.41
Contingent Liabilities	0.00	310.53	87.93	48.71	24.87

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Assets	1,750.12	1,696.58	1,552.20	1,223.26	1,094.19
Total Assets Growth (%)	3.16	9.30	26.89	11.80	-10.64
Total Liabilities	379.96	372.53	333.89	491.30	416.24
Total Liabilities Growth (%)	1.99	11.57	-32.04	18.03	-23.36
Total Equity	1,370.15	1,324.05	1,218.32	731.96	677.95
Total Equity Growth (%)	3.48	8.68	66.45	7.97	-0.50
Current Ratio (x)	3.48	3.31	3.73	1.51	2.25
Total Debt to Equity (x)	0.13	0.13	0.11	0.45	0.40
Contingent Liabilities	0.00	543.77	59.23	44.91	24.87

All figures in Rs Cr, unless mentioned otherwise

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Net Cash flow from Operating Activities	101.20	19.22	125.99	18.34	92.47
Net Cash used in Investing Activities	-285.27	-26.93	-312.03	-31.21	112.94
Net Cash flow from Financing Activities	169.98	25.22	167.04	31.17	-216.80
Net Cash Flow	-14.10	17.51	-19.00	18.29	-11.39
Closing Cash & Cash Equivalent	7.01	21.11	3.60	22.60	4.31
Closing Cash & Cash Equivalent Growth (%)	-66.80	486.13	-84.06	424.71	-72.56
Total Debt/ CFO (x)	3.53	9.07	1.07	18.07	2.90

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Net Cash flow from Operating Activities	118.64	27.48	130.73	13.39	89.57
Net Cash used in Investing Activities	-125.37	-37.35	-315.81	-26.70	112.93
Net Cash flow from Financing Activities	-7.90	25.44	167.07	31.17	-216.80
Net Cash Flow	-14.63	15.58	-18.01	17.86	-14.30
Closing Cash & Cash Equivalent	1.24	15.87	0.29	18.31	0.45
Closing Cash & Cash Equivalent Growth (%)	-92.19	5,285.41	-98.39	3,966.57	-96.95
Total Debt/ CFO (x)	1.51	6.34	1.03	24.75	2.99

All figures in Rs Cr, unless mentioned otherwise

Insights

Increase in Cash from Investing
Company has used Rs 285.27 cr for investing activities which is an YoY increase of 959.25%. (Source: Consolidated Financials)

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Return on Equity (%)	1.59	7.86	7.88	6.72	-0.30
Return on Capital Employed (%)	2.50	7.85	8.37	5.65	-2.86
Return on Assets (%)	1.07	5.90	5.93	3.78	-0.17
Interest Coverage Ratio (x)	5.75	9.95	8.65	3.20	1.94
Asset Turnover Ratio (x)	0.45	0.57	0.59	0.57	0.48
Price to Earnings (x)	119.05	39.68	57.80	33.90	-625.00
Price to Book (x)	1.88	3.11	4.53	2.28	1.79
EV/EBITDA (x)	35.39	27.20	36.52	18.14	22.86
EBITDA Margin (%)	9.40	15.69	17.27	15.47	11.10

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Return on Equity (%)	3.29	8.04	7.77	7.40	-0.70
Return on Capital Employed (%)	4.14	8.29	8.03	5.38	3.80
Return on Assets (%)	2.58	6.27	6.10	4.42	-0.43
Interest Coverage Ratio (x)	7.60	10.69	8.64	3.20	0.76
Asset Turnover Ratio (x)	0.47	0.57	0.59	0.57	0.48
Price to Earnings (x)	53.76	37.04	56.18	28.99	-243.90
Price to Book (x)	1.77	2.98	4.35	2.14	1.71
EV/EBITDA (x)	25.25	25.41	36.71	18.22	21.49
EBITDA Margin (%)	12.39	16.86	17.21	15.47	11.89

Found Financials useful?

Share Price Forecast

Exclusively for ETPrime

REVENUE
Invest in the Best
Check two-year estimates on Price, Revenue & Earnings
READ FOR FREE ON APP
EARNINGS
Invest in the Best
Check two-year estimates on Price, Revenue & Earnings
READ FOR FREE ON APP
PRICE
Invest in the Best
Check two-year estimates on Price, Revenue & Earnings
READ FOR FREE ON APP

Technicals

Buy/Sell Signals
No Data Available
Price Analysis
No Data Available
Pivot Levels
R1 - Pivot
-
S1 -
R2 - S2 -
R3 - S3 -
Average True Range
5 Days 14 Days 28 Days
- - -

Peer Comparison

Ratio Performance

NAME	P/E (x)	P/B (x)	ROE %	ROCE %	ROA %	Rev CAGR [3Yr]	OPM	NPM	Basic EPS	Current Ratio	Total Debt/ Equity (x)	Total Debt/ CFO (x)
Orchid Pharma	228.53	3.61	1.59	2.50	1.07	7.22	5.03	2.61	4.05	2.45	0.28	3.53
Gujarat Themis	90.40	14.66	16.22	15.32	9.27	2.74	39.22	28.15	4.28	1.12	0.56	3.28
IOL Chemicals	28.63	2.19	7.65	11.07	5.32	1.42	9.06	5.93	4.69	1.78	0.07	0.62
Gufic BioSci	57.98	5.60	9.65	14.93	4.78	10.83	13.04	6.80	6.40	1.55	0.58	8.57
RPG Life Sci	31.83	6.06	19.02	23.89	14.52	12.17	21.36	16.27	69.64	3.52	0.03	0.35
Add More

Annual Ratios (%)

Choose from Peers

Aarti Drugs
Unichem Labs
Solara Active Pharma
Dishman Carbogen
Morepen Labs

Choose from Stocks

Stock Performance

CHART
TABLE

1D
1W
1M
3M
6M
1Y
5Y

Choose from Peers
Choose from Stocks

Shareholding Pattern

Total Shareholdings
Category No. of Shares Percentage % Change QoQ
Promoters 3,54,19,957 69.84 % 0.00
Pledge 0 0.00 % 0.00
FII 4,41,158 0.87 % -0.30
DII 1,02,37,375 20.18 % 0.85
MF 98,56,296 19.43 % 1.41
Others 46,20,615 9.10 % -0.56
QoQ Change
Category Mar 2026 Dec 2025 Sep 2025 Jun 2025
Promoters 69.84 69.84 69.84 69.84
Pledge 0.00 0.00 0.00 0.00
FII 0.87 1.17 1.56 1.39
DII 20.18 19.32 18.98 19.36
Mutual Funds 19.43 18.01 18.04 18.58
Others 9.10 9.66 9.61 9.40

Mutual Funds Ownership

MF Ownership as on 30 April 2026

Quant Small Cap Direct-G
Equity: Small Cap
3
- 216.88
  Amount Invested (in Cr.)
- 0.714044%
  % of AUM
- 0.00
  % Change (MoM basis)
UTI Value Direct-G
Equity: Value Oriented
3
- 86.04
  Amount Invested (in Cr.)
- 0.91212331%
  % of AUM
- 0.00
  % Change (MoM basis)
Invesco India Contra Direct-G
Equity: Value Oriented
3
- 62.00
  Amount Invested (in Cr.)
- 0.32%
  % of AUM
- 0.00
  % Change (MoM basis)

View all Mutual Fund Schemes

Orchid Pharma Top Searches

Corporate Actions

Recent
Board Meeting
Audited Results
May 19, 2026
Board Meeting
Quarterly Results
Feb 06, 2026
Board Meeting
Quarterly Results
Nov 06, 2025

Announced on	Meeting on
May 19, 2026	May 25, 2026
Audited Results
Feb 06, 2026	Feb 11, 2026
Quarterly Results
Nov 06, 2025	Nov 11, 2025
Quarterly Results
Aug 05, 2025	Aug 12, 2025
Quarterly Results
May 20, 2025	May 26, 2025
Audited Results

Dividends
Announced on Ex-Date Dividend%
May 15, 2012 Sep 13, 2012 30%
May 18, 2011 Jul 19, 2011 30%
May 28, 2010 Jul 12, 2010 100%
Jun 30, 2009 Sep 17, 2009 10%
May 29, 2008 Sep 18, 2008 30%
Bonus
Announced on Ex-Date
Jul 18, 2005 Sep 15, 2005
Bonus Ratio: 1 share(s) for every 2 shares held
Splits
No Data Available
Rights
Announced on Ex-Date
Mar 15, 1995 Jan 09, 1995
Rights ratio: 1 share for every 1 held at a price of Rs 40.0
AGM/EGM Meetings
Announced on Meeting on
Aug 28, 2025 Sep 20, 2025
-
May 27, 2025 Jun 26, 2025
-
Jul 24, 2024 Aug 21, 2024
-
Oct 23, 2023 Nov 29, 2023
-
Jul 13, 2023 Aug 09, 2023
A.G.M.

About Orchid Pharma

Orchid Pharma Ltd., incorporated in the year 1992, is a Small Cap company (having a market cap of Rs 4,651.45 Crore) operating in Pharmaceuticals sector.

Orchid Pharma Ltd. key Products/Revenue Segments include Pharmaceutical Products, Other Operating Revenue, Other Materials and Sale of services for the year ending 31-Mar-2025.

For the quarter ended 31-03-2026, the company has reported a Consolidated Total Income of Rs 244.95 Crore, up 15.07 % from last quarter Total Income of Rs 212.88 Crore and up 1.48 % from last year same quarter Total Income of Rs 241.38 Crore. Company has reported net profit after tax of Rs 22.79 Crore in latest quarter.

The company’s top management includes Mr.Ram Gopal Agarwal, Mr.Manish Dhanuka, Mr.Mridul Dhanuka, Mr.Arjun Dhanuka, Dr.Dharam Vir, Dr.Manoj Kumar Goyal, Ms.Shubha Singh, Mrs.Tanu Singla, Mr.Sunil Kumar Gupta, Mr.Kapil Dayya. Company has Singhi & Co. as its auditors. As on 31-03-2026, the company has a total of 5.07 Crore shares outstanding.

Orchid Pharma Share Price Today is Rs. 917.10. On previous day, the Orchid Pharma Share Price (NSE) closed at Rs. 845.95, featuring among the most traded securities on the National Stock Exchange.

Shareholdings:
As of 31st Mar, 2026, the promoter held 69.84% of the stake in Orchid Pharma shares, out of which 0.0% was pledged. On the same date, foreign institutional investors' (FII) holdings of Orchid Pharma stocks was 0.87% as compared to 1.17% in Dec 2025 with decrease of 0.3%. The domestic institutional investors (DII) holdings on 31st Mar, 2026 was 20.18% as compared to 19.32% in Dec 2025 with increase of 0.86%. Out of the total DII holdings in Orchid Pharma shares 19.43% was held by mutual funds. The rest including public held is 9.11%. Orchid Pharma stock price is reflected on both the exchanges - BSE and NSE.

Dividend, Bonus & Split Information:
Orchid Pharma Dividend: Ever since 1992, Orchid Pharma dividends has been paid out around 18 times. As on 12 Jun, 2026, 03:52 PM IST, The overall dividend yield for Orchid Pharma stands at 0.0%. The last dividend paid was on null (Rs. null). The Earnings Per Share (EPS) for quarter ending 31st Mar 2026 is Rs. 4.01.

Orchid Pharma Bonus: The most recent bonus issue had been in year September 15, 2005 around 20 years ago at 2 : 1 ratio. The first bonus issue was announced in Jul 2005.

Stock Forecast:
After showing 244.95 Cr. of sales and 15.07% of quarterly net profit, there have been multiple ups and downs in the Orchid Pharma stock prices in the past few weeks. For example, Orchid Pharma stock price on 5th of June 2026 was around Rs. 844.25. Orchid Pharma share price now stands at an average of Rs. 917.10. Judging by last week's performance, stock is in up trend.

Orchid Pharma has a median target price of Rs. 1083.0 in 12 months by 1 analysts. They have provided a high estimate of Rs. 1083.0 and low estimate of Rs. 1083.0 for Orchid Pharma share.

Historical Prices and Performance:
Orchid Pharma,incorporated in 1992 is a Small Cap company (with a market cap of Rs. 4651.45) operating in Pharmaceuticals sector.
The Return of Equity (ROE) in last five financial years given by Orchid Pharma stock was 1.59%, 7.86%, 7.88%, 6.72% and -0.3% respectively.
The Orchid Pharma share gave a 3 year return of 120.91% as compared to Nifty 50 which gave a return of 26.99%.
Orchid Pharma announced 0.0% final dividend on null.

Key Metrics:
PE Ratio of Orchid Pharma is 210.8
Prices/Sales Ratio of Orchid Pharma is 2.99
Price/Book Ratio of Orchid Pharma is 3.33

Peer Insights:
Peers are businesses with comparable activities, buisness objectives and affiliation with a particular industry area. For Orchid Pharma,major competitors and peers include Gujarat Themis, IOL Chemicals, Gufic BioSci and RPG Life Sci. As of Dec 2025, the dividend yield of Orchid Pharma stands at 0.0% while Gujarat Themis, IOL Chemicals, Gufic BioSci and RPG Life Sci stand at 0.17%, 0.74%, 0.03% and 1.08% respectively. The PE ratio and PB Ratio of the company are among its competitors stand at 210.8 and 3.33 respectively.

Leadership of Orchid Pharma :
Sunil Kumar Gupta is Chief Financial Officer
Kapil Dayya is Co. Secretary & Compl. Officer
Ram Gopal Agarwal is Chairman & Non-Exe.Director
Manish Dhanuka is Managing Director
Mridul Dhanuka is Whole Time Director
Arjun Dhanuka is Non Executive Director
Tanu Singla is Independent Woman Director
Dharam Vir is Independent Director
Manoj Kumar Goyal is Independent Director
Shubha Singh is Independent Woman Director

Show More

Industry

Pharma - Indian

Key Indices Listed On

BSE SmallCap, BSE Healthcare, BSE AllCap, BSE Next 250 Microcap, Nifty Smallcap 500

Address

Plot Nos. 121-128, 128A-133, 138-151, 159-164,SIDCO Industrial Estate, Alathur,Chengalpattu, Tamil Nadu - 600110

Contact

corporate@orchidpharma.com

http://www.orchidpharma.com

Executive Leadership

RG

Ram Gopal Agarwal

Chairman & Non-Exe.Director

MD

Manish Dhanuka

Managing Director

MD

Mridul Dhanuka

Whole Time Director

AD

Arjun Dhanuka

Non Executive Director

Show More

Auditors

Singhi & Co.

CNGSN & Associates LLP

FAQs about Orchid Pharma share

1. What's Orchid Pharma share price today and what are Orchid Pharma share returns ?
As on 12 Jun, 2026, 03:52 PM IST Orchid Pharma share price is up by 8.42% basis the previous closing price of Rs 850.95. Orchid Pharma share price is Rs 917.10. Return Performance of Orchid Pharma Shares:
- 1 Week: Orchid Pharma share price moved up by 8.63%
2. What is the market cap of Orchid Pharma ?
Within the Pharmaceuticals sector, Orchid Pharma stock has a market cap rank of 61. Orchid Pharma has a market cap of Rs 4,651.45 Cr.
3. What is the PE & PB ratio of Orchid Pharma ?
The PE ratio of Orchid Pharma stands at 210.8, while the PB ratio is 3.33.
4. What is Orchid Pharma 's 52 week high / low?
52 Week high of Orchid Pharma share is Rs 935.00 while 52 week low is Rs 480.00
5. What are the returns for Orchid Pharma share?
Return Performance of Orchid Pharma Shares:
- 1 Week: Orchid Pharma share price moved up by 8.63%

Top Gainers

As on 04:06 PM | 12 Jun 2026

1,028.70

714.90 (227.82%)

Netweb Technologies

4,587.40

2780.60 (153.90%)

Syrma SGS Technology

1,266.70

737.70 (139.45%)

14.90

8.12 (119.76%)

4,942.50

2633.90 (114.09%)

Top Losers

As on 03:58 PM | 12 Jun 2026

Tata Investment

665.90

-6218.10 (-90.33%)

339.50

-2678.10 (-88.75%)

757.55

-3315.15 (-81.40%)

403.30

-1723.50 (-81.04%)

Authum Investment

530.15

-1967.65 (-78.78%)

Equity Quick Links

Top Gainers
Top Losers
Hourly gainers
Hourly losers
Sensex
Nifty
NSE
BSE

Midcap stocks
Smallcap stocks
Largecap stocks
Sensex
Nifty
NSE
BSE
MCX Live

More from Markets

IPO
Stock market news
Budget 2022 Live Updates
Cryptocurrency
Currency converter
NSE holiday list

Trending in Markets

DATA SOURCES: TickerPlant (for live BSE/NSE quotes service) and Dion Global Solutions Ltd. (for corporate data, historical price & volume, F&O data). Sensex & BSE Quotes and Nifty & NSE Quotes are real-time and licensed from BSE and NSE respectively. All timestamps are reflected in IST (Indian Standard Time).

DISCLAIMER: Any and all content on this website including tools/analysis is provided to you only for convenience and on an “as-is, as- available” basis without representation and warranties of any kind. The content and any output of such tools/analysis is for informational purposes only and should not be relied upon or construed as an investment advice or guarantee for any specific performance/returns advice or considered as recommendation for the purchase or sale of any security or investment. You are advised to exercise caution, discretion and independent judgment with regards to the same and seek advice from professionals and certified experts before taking any decisions.

By using this site, you agree to the Terms of Service and Privacy Policy.